Similar articles

• Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!

  Samur M, Bozcuk HS. Samur M, et al. J Clin Oncol. 2003 Jun 15;21(12):2444; author reply 2445-7. doi: 10.1200/JCO.2003.99.014. J Clin Oncol. 2003. PMID: 12805349 No abstract available.
• Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management?

  Kohli M, Khan MA, Mehta P, Hutchins L. Kohli M, et al. J Clin Oncol. 2003 Jun 15;21(12):2445. doi: 10.1200/jco.2003.99.029. J Clin Oncol. 2003. PMID: 12805351 No abstract available.
• Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

  Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study. Jonat W, et al. J Clin Oncol. 2002 Dec 15;20(24):4628-35. doi: 10.1200/JCO.2002.05.042. J Clin Oncol. 2002. PMID: 12488406
• Controversies in the treatment of cancer of the breast.

  Swain SM, Lippman ME. Swain SM, et al. Annu Rev Med. 1987;38:287-94. doi: 10.1146/annurev.me.38.020187.001443. Annu Rev Med. 1987. PMID: 3555297 Review.
• Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer.

  Stevens A, Spooner D. Stevens A, et al. Clin Oncol (R Coll Radiol). 2001;13(6):438-40. doi: 10.1053/clon.2001.9308. Clin Oncol (R Coll Radiol). 2001. PMID: 11824881 Review.